Status:
COMPLETED
Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
VA Office of Research and Development
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally administered nicotinic cholinergic agonist, will improve attention and other neuropsychological dysfunctions in s...
Detailed Description
The objective of the trial is to determine if dosing 3-(2,4 dimethoxybenzylidene anabaseine) twice daily for 4 weeks will improve cognition and be safe. Secondary goals are to determine if these neuro...
Eligibility Criteria
Inclusion
- Schizophrenia
- Currently treated with neuroleptic drugs
Exclusion
- Treatment with clozapine;
- Head injury or neurological condition;
- Cardiovascular disease;
- Substance abuse or dependence, including nicotine
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00100165
Start Date
January 1 2005
End Date
July 1 2007
Last Update
January 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Eastern Colorado Health Care System, Denver, CO
Denver, Colorado, United States, 80220